FindTrial
Sign In

An Open Cohort Study on the Long-term Survival Impact of Huoling Shengji Granules in Patients with Amyotrophic Lateral Sclerosis (Deficiency of Spleen Qi and Kidney Yang Deficiency Syndrome)

An Open Cohort Study on the Long-term Survival Impact of Huoling Shengji Granules in Patients with Amyotrophic Lateral Sclerosis (Deficiency of Spleen Qi and Kidney Yang Deficiency Syndrome)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025000558
Enrollment
Unknown
Registered
2025-03-20
Start date
2025-04-07
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic lateral sclerosis

Interventions

The Riluzole group:Retrospectively collect cases of patients who used Riluzole Tablets
The Huoling Shengji group:Retrospectively collect cases of patients who used Huoling Shengji Granules

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 69 Years

Inclusion criteria

Inclusion criteria: Patients who have previously participated in the clinical trial of Huoling Shengji Granules (Protocol Number: Z-HLSJ-GR-2020-KCYY-01) and were randomized among the 144 cases.

Exclusion criteria

Exclusion criteria: Patients who have not previously participated in the clinical trial of Huoling Shengji Granules (Protocol Number: Z-HLSJ-GR-2020-KCYY-01)

Design outcomes

Primary

MeasureTime frame
Overall survival;—

Secondary

MeasureTime frame
ROADS;Ventilator-free survival;Endpoint event incidence rate;Tracheostomy-free survival;—

Countries

China

Contacts

Public ContactDongsheng Fan

Peking University Third Hospital

dsfan@sina.com010-82265032

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026